TruAlt Bioenergy

Why is TruAlt Bioenergy Ltd falling/rising?

As of 09-Aug, TruAlt Bioenergy Ltd's stock price is at 476.80, reflecting a 2.55% increase and strong performance with a 12.85% return over the past week. The stock is trading above key moving averages and has outperformed its sector, indicating positive momentum despite a slight decline in investor participation.

As of 09-Aug, TruAlt Bioenergy Ltd's stock price is rising, currently at 476.80, reflecting a change of 11.85 (2.55%) upward. The stock has shown strong performance over the past week, with a return of +12.85%, significantly outperforming the Sensex, which only increased by +0.52% during the same period. Additionally, the stock has gained 9.08% over the last three days, indicating a positive momentum.<BR><BR>Today's trading performance also highlights that TruAlt Bioenergy has outperformed its sector by 2.7%. The stock reached an intraday high of Rs 483, marking a rise of 3.88%. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal for investors.<BR><BR>Despite a slight decline in investor participation, with delivery volume decreasing by 4.85% against the 5-day average, the stock remains liquid enough for trading, with a value of Rs 0.28 crore based on 2% of the 5-day average traded value. Positive financial results, including a significant growth in profit before tax and net sales, contribute to the stock's attractive valuation, further supporting its upward price movement.

Which are the latest news on TruAlt Bioenergy?

Are TruAlt Bioenergy Ltd latest results good or bad?

TruAlt Bioenergy Ltd's latest results show strong year-on-year growth, with net sales up 106.29% and net profit increasing by 1,108.25%. However, sequential declines in profit and margins raise concerns about the sustainability of this growth, indicating a mixed overall performance.

TruAlt Bioenergy Ltd's latest results present a mixed picture. On one hand, the company achieved impressive year-on-year growth, with net sales increasing by 106.29% to ₹626.88 crores compared to the same quarter last year. This recovery is notable, especially considering the weak performance in the previous year. However, the sequential quarter-on-quarter growth of just 5.27% indicates that the momentum may be slowing down after a strong performance in prior quarters.<BR><BR>In terms of profitability, the net profit for Q1 FY27 was ₹57.15 crores, reflecting an extraordinary year-on-year increase of 1,108.25%. However, this represents a decline of 15.79% compared to the previous quarter, which raises concerns about the sustainability of profit levels. Additionally, while the operating margin improved significantly year-on-year to 21.18%, it did see a slight decline from the previous quarter.<BR><BR>Overall, while the year-on-year growth figures are strong and suggest a recovery from past challenges, the sequential declines in profit and margins indicate potential issues that need to be monitored closely. The company is still navigating through operational volatility and capital efficiency challenges, which could impact its long-term performance. Therefore, the results can be viewed as good in terms of recovery but concerning regarding the sustainability of that growth.

Should I buy, sell or hold TruAlt Bioenergy Ltd?

What does TruAlt Bioenergy do?

TruAlt Bioenergy Ltd is a small-cap company in the commodity chemicals industry, reporting net sales of 596 Cr and a net profit of 60 Cr for the quarter ending March 2026, with a market cap of INR 4,595 Cr. Key metrics include a P/E ratio of 46.00 and a debt-equity ratio of 1.01.

Overview: <BR>TruAlt Bioenergy Ltd operates in the commodity chemicals industry and is categorized as a small-cap company.<BR><BR>History: <BR>The incorporation year is not specified, and there are no status changes mentioned. The latest quarter for which sales and profit are reported is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 596 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 60 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4,595 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.01 <BR>Return on Equity: 5.29% <BR>Price to Book: 3.01 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is TruAlt Bioenergy?

As of 10th June, TruAlt Bioenergy Ltd has a market capitalization of 4,595.00 Cr, with recent net sales of 1,727.51 Cr and a net profit of 96.00 Cr. Shareholder's funds are 769.00 Cr, and total assets amount to 3,029.73 Cr.

As of 10th June, TruAlt Bioenergy Ltd has a market capitalization of 4,595.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, TruAlt Bioenergy reported Net Sales of 1,727.51 Cr and a Net Profit of 96.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 769.00 Cr and Total Assets of 3,029.73 Cr.

Who are the peers of the TruAlt Bioenergy?

TruAlt Bioenergy's peers include Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Tanfac Inds., and others. Management risk varies from excellent at GHCL and Chemplast Sanmar to below average at Fischer Medical, with Tanfac Inds. showing the highest 1-year return at 20.05% and GHCL the lowest at -32.65%.

Peers: The peers of TruAlt Bioenergy are Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, Chemplast Sanmar, Fischer Medical, Thirumalai Chem., J.G.Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, Gujarat Alkalies, Tanfac Inds., Grauer & Weil, Thirumalai Chem., and J.G.Chemicals, and the rest. Below Average management risk is noted at Fischer Medical. Growth is rated as Excellent for Fischer Medical, Good for Tanfac Inds. and J.G.Chemicals, while Below Average growth is seen at Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., and the rest. Average capital structure is present at Tata Chemicals, India Glycols, and Thirumalai Chem., while Excellent capital structure is noted for Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, and J.G.Chemicals, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tanfac Inds. at 20.05%, while the lowest is GHCL at -32.65%. TruAlt Bioenergy's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include GHCL, Fischer Medical, Thirumalai Chem., and Chemplast Sanmar.

When is the next results date for TruAlt Bioenergy Ltd?

The next results date for TruAlt Bioenergy Ltd is 22 May 2026.

The next results date for TruAlt Bioenergy Ltd is scheduled for 22 May 2026.